SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending following a strong earnings beat and robust Q1 guidance driven by surging data center demand, sparking intense community debate despite the impressive financials. While many anticipate a significant rally, others caution of a 'sell the news' scenario, citing ongoing skepticism regarding AI valuation and perceived market manipulation impacting options traders.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desk (TTD) is experiencing a significant sell-off after providing softer-than-expected Q1 guidance, despite beating Q4 revenue and earnings estimates, fueling intense investor debate. Many express frustration over the prolonged stock decline and executive compensation, while others view the sharp drop as an oversold opportunity, highlighting the company's profitability and strong customer retention in the competitive ad tech sector.

Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.

Larimar Therapeutics Inc

Larimar Therapeutics is trending after receiving FDA Breakthrough Therapy Designation for its Friedreich's ataxia treatment, igniting bullish comparisons to multi-billion dollar acquisitions, though a recently priced $100 million public offering is fueling debate among investors over dilution versus strategic funding for commercialization.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

Infinite Money Glitch (IMG CRYPTO) is trending as its community celebrates a one-year anniversary and the recent launch of its "incinerator," which executes continuous buybacks and burns to tighten supply. Holders are bullish on its passive income mechanism, which automatically distributes Solana rewards.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

An increase in ImmunityBio's (IBRX) shares outstanding, stemming from debt conversion and founder Patrick Soon-Shiong's reaffirmed majority ownership, is driving fervent community debate over the stock's true free float and massive short interest; this occurs amidst recent global regulatory approvals and significant revenue growth, leaving bulls anticipating a short squeeze while skeptics raise dilution concerns.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals (AUPH) is actively discussed ahead of its Q4 earnings report, with investor sentiment focused on overdue updates for the AUR200 Phase 2 pipeline and continued Lupkynis sales performance. Community hopes for a significant catalyst, potentially a buyout, are tempered by past management communication issues, despite notable institutional accumulation.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is trending due to its recent earnings report, emphasizing its critical role in advanced GaN and SiC power solutions for next-gen AI data centers and EVs, especially within NVIDIA's ecosystem. The community is keenly watching for concrete, revenue-generating partnerships that could validate its long-term potential, despite current revenue declines prompting market debate.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as its earnings approach, driven by heightened speculation around new Matrix-M licensing deals in oncology and for C. diff, fueling community hopes for a short squeeze and a resolution to long-standing frustrations over strategic execution.

Direxion Shares ETF Trust - Direxion Daily South Korea Bull 3X Shares

Direxion Daily South Korea Bull 3X Shares

KORU is skyrocketing on an extraordinary rally in South Korean equities, propelled by semiconductor powerhouses Samsung and SK Hynix amid booming High Bandwidth Memory chip demand for AI processing. The community is actively discussing its immense gains, anticipating further momentum from the country's recent short-selling ban and ongoing market reforms.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle (CRCL) is rallying significantly after a strong Q4 earnings report highlighted robust growth in USDC circulation and adjusted EBITDA, propelling community discussion about its role as a foundational stablecoin platform. Bulls anticipate a substantial short squeeze and triple-digit price targets, while a vocal contingent of bears warns of an overextended rally ripe for profit-taking amidst ongoing debates about its valuation and crypto market correlation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Given New $53.00 Price Target at Wells Fargo & Company

Wells Fargo & Company raised their price objective on shares of Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the company an "overweight" rating in a report on Wednesday...

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Given New $53.00 Price Target at Wedbush

Wedbush increased their target price on shares of Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the stock an "outperform" rating in a research report on Wednesday...

Kiniksa Pharmaceuticals International Q4 Earnings Call Highlights

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) reported fourth-quarter and full-year 2025 results highlighting continued growth for ARCALYST in recurrent pericarditis, a return to profitability...

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Shares Gap Down on Disappointing Earnings

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Shares Gap Down Following Weak Earnings...

Kiniksa Pharmaceuticals International, plc (KNSA) Misses Q4 Earnings Estimates

Kiniksa Pharmaceuticals International, plc (KNSA) delivered earnings and revenue surprises of -40.71% and +0.66%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Releases Quarterly Earnings Results, Misses Estimates By $0.20 EPS

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported $0.17 earnings per share for the quarter, missing analysts...

Do Options Traders Know Something About KNSA Stock We Don't?

Investors need to pay close attention to Kiniksa Pharmaceuticals International stock based on the movements in the options market lately.

Kiniksa Pharmaceuticals International, plc $KNSA Shares Bought by Hillsdale Investment Management Inc.

Hillsdale Investment Management Inc. grew its holdings in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) by 12.4% in the 3rd quarter, according to the company in its...

Aberdeen Group plc Buys New Position in Kiniksa Pharmaceuticals International, plc $KNSA

Aberdeen Group plc bought a new position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) in the 3rd quarter, according to the company in its most recent disclosure...

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Reaches New 52-Week High - Here's Why

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Reaches New 1-Year High - Time to Buy...

$KNSA Q4 &#39;25 Earnings Results &amp; Recap

• Reported GAAP EPS of $0.19 up 258.33% YoY
• Reported revenue of $202.13M up 64.95% YoY
• Kiniksa expects 2026 ARCALYST net product revenue to be between $900M and $920M. Kiniksa also anticipates its current operating plan will remain cash flow positive on an annual basis.

Stocktwits

Kiniksa Pharmaceuticals Ltd - Ordinary Shares - Class A

 Q4 '25 Earnings Results & Recap

• Reported GAAP EPS of $0.19 up 258.33% YoY
• Reported revenue of $202.13M up 64.95% YoY
• Kiniksa expects 2026 ARCALYST net product revenue to be between $900M and $920M. Kiniksa also anticipates its current operating plan will remain cash flow positive on an annual basis.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

$KNSA Q4 &#39;25 Earnings Results &amp; Recap

• Reported GAAP EPS of $0.19 up 258.33% YoY
• Reported revenue of $202.13M up 64.95% YoY
• Kiniksa expects 2026 ARCALYST net product revenue to be between $900M and $920M, and the company&#39;s current operating plan is anticipated to remain cash flow positive on an annual basis.

 Q4 '25 Earnings Results & Recap

• Reported GAAP EPS of $0.19 up 258.33% YoY
• Reported revenue of $202.13M up 64.95% YoY
• Kiniksa expects 2026 ARCALYST net product revenue to be between $900M and $920M, and the company's current operating plan is anticipated to remain cash flow positive on an annual basis.

Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. It engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The company was founded on April 9, 2024 and is headquartered in London, United Kingdom.

Current Price	$42.76
Prev Close	$43.50
Open	$43.50
Dividend Yield	0.00%
50-Day Moving Average	$42.82
Beta	0.73
Avg. Volume	736,242.30
PE Ratio	58.68

52-Week High	$49.12
52-Week Low	$18.26
Market Capitalization	$3.3B
EPS (Annual)	$0.75
Price to Book	6.13
Revenue Per Employee	$2.15M

KNSA
Kiniksa Pharmaceuticals Ltd - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest KNSA News

KNSAKiniksa Pharmaceuticals Ltd - Ordinary Shares - Class A